The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Susan Mary O'Brien
Research Funding - Gilead Sciences
Nicole Lamanna
Research Funding - Gilead Sciences
Thomas J. Kipps
Research Funding - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences
Andrew David Zelenetz
Research Funding - Gilead Sciences
Jan Andreas Burger
Research Funding - Gilead Sciences
Leanne Holes
Employment or Leadership Position - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Jessie Gu
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Ronald L. Dubowy
Employment or Leadership Position - Gilead Sciences
Steven E. Coutre
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences